5-乙酰基-6-甲基-2-氧代-1,2-二羟基吡啶-3-甲腈 | 52600-53-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-乙酰基-6-甲基-2-氧代-1,2-二羟基吡啶-3-甲腈
• 中文别名: 5-乙酰基-6-甲基-2-羟基吡啶-3-甲腈；5-乙酰-2-羟基-6-甲基烟碱
• 英文名称: 5-acetyl-1,2-dihydro-6-methyl-2-oxonicotinonitrile
• 英文别名: 5-acetyl-6-methyl-1,2-dihydro-2-oxo-3-pyridinecarbonitrile；SF 28；3-cyano-5-acetyl-6-methylpyridin-2(1H)-one；5-acetyl-6-methyl-2-oxo-1,2-dihydro-pyridine-3-carbonitrile；5-Acetyl-3-cyano-6-methyl-2-pyridone；5-acetyl-1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile；2-methyl-3-acetyl-5-cyano-6-pyridone；5-acetyl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile
• CAS: 52600-53-0
• 化学式: C₉H₈N₂O₂
• mdl: MFCD00174249
• 分子量: 176.175
• InChiKey: BPHCKZKXAHIRPD-UHFFFAOYSA-N

物化性质

• 熔点：
  233-235°

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  70
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S36/37
• 危险类别码：
  R20/21/22
• 海关编码：
  2933399090

SDS

Name:	5-Acetyl-6-methyl-2-oxo-1 2-dihydropyridine-3-carbonitrile 97% Material Safety Data Sheet
Synonym:	5-Acetyl-3-cyano-6-methyl-2-pyridon
CAS:	52600-53-0

Section 1 - Chemical Product MSDS Name:5-Acetyl-6-methyl-2-oxo-1 2-dihydropyridine-3-carbonitrile 97% Material Safety Data Sheet
Synonym:5-Acetyl-3-cyano-6-methyl-2-pyridon

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
52600-53-0	5-Acetyl-6-methyl-2-oxo-1,2-dihydropyr	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 52600-53-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 226 - 228 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8N2O2
Molecular Weight: 176

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Bases, oxidizing agents.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 52600-53-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Acetyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 52600-53-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 52600-53-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 52600-53-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-乙酰基-6-甲基-2-氧代-1,2-二羟基吡啶-3-甲腈 在 palladium on activated charcoal 正丁基锂 、 diisobutylammonium hydride 、 氢气 、 silver carbonate 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 、 苯 为溶剂， -78.0~25.0 ℃ 、101.33 kPa 条件下， 反应 22.08h， 生成 3-[2-(Benzoxazol-2-yl)ethyl]-5-isopropyl-6-methylpyridin-2(1H)-one
  参考文献：
  名称：

  合成和评估2-吡啶酮衍生物作为HIV-1特异性逆转录酶抑制剂。4. 3- [2-（苯并恶唑-2-基）乙基] -5-乙基-6-甲基吡啶-2（1H）-one及其类似物。

  摘要：

  基于初步开发的3-[（（邻苯二甲酰亚胺基）乙基] -5-乙基-6-甲基吡啶-2（1H）-一]（3）铅，开发了一系列新的有效的特定2-吡啶酮逆转录酶（RT）抑制剂，一种非核苷衍生物，在细胞培养中对HIV-1株IIIB表现出弱的抗病毒活性。一种化合物3-[（苯并恶唑-2-基）乙基] -5-乙基-6-甲基吡啶-2（1H）-一（9，L-696,229），是RT酶的高度选择性拮抗剂（IC50 （= 23 nM）且在MT4人T淋巴细胞培养物中（CIC95 = 50-100 nM）将HIV-1 IIIB感染的传播抑制> 95％（CIC95 = 50-100 nM），作为抗病毒药物进行临床评估。

  DOI：

  10.1021/jm00060a002
• 作为产物：
  描述：

  乙酰丙酮 在 sodium hydride 作用下， 生成 5-乙酰基-6-甲基-2-氧代-1,2-二羟基吡啶-3-甲腈
  参考文献：
  名称：

  5-酰基-6-取代的3-氰基-2（1 H）-吡啶酮的便捷合成

  摘要：

  2-二甲基氨基亚甲基-1，3-二酮是用于构建5-酰基-6-取代的-3-氰基-2（1 H）-吡啶酮的有用的合成子。这些1，3-二酮与氰基乙酰胺的阴离子反应，得到标题化合物。当1，3-二酮包含不同的烷基或芳基时，形成区域异构体的混合物。为了解决这个问题，使由二甲基肼基烯酮和二甲基甲酰胺二甲基乙缩醛区域选择性制备的二甲基氨基亚甲基与氰基乙酰胺阴离子反应，然后酸水解，得到标题化合物。

  DOI：

  10.1002/jhet.5570270307

文献信息

• Imidazo(1,2-a)pyridines. I. Synthesis and Inotropic Activity of New 5-Imidazo(1,2-a)pyridinyl-2(1H)-pyridinone Derivatives.
  作者：Motosuke YAMANAKA、Kazutoshi MIYAKE、Shinji SUDA、Hideto OHHARA、Toshiaki OGAWA

  DOI：10.1248/cpb.39.1556

  日期：——

  A series of 1, 2-dihydro-5-imidazo[1, 2-α]pyridinyl-2(1H)-pyridonones was synthesized and evaluated for positive inotropic activity. 1, 2-Dihydro-5-imidazo[1, 2-α]pyridin-6-yl-6-methyl-2-oxo-3-pyridinecarbonitrile (11a) hydrochloride monohydrate (E-1020) was found to be a potent and selective inhibitor of phosphodiesterase III and a long-acting, potent, orally active positive inotropic agent. Additional imidazo[1, 2-α]pyridin-2-yl (3a), -3-yl (16), -7-yl (20) and -8-yl (24a) compounds were also prepared. Altering the pyridine substitution from the 2-position to the 6-position produced a 2-fold increse in the i.v. cardiotonic potency (ED50) from 52 to 23 μg/kg, while substitution at the 3-, 7- or 8-position reduced potency. In the 2-positional isomers, introduction of halogen groups enhanced the activity and 3-chloro-1, 2-dihydro-5-(6-fluoroimidazo[1, 2-α]pyridin-2-yl)-6-methyl-2(1H)-pyridinone (3u) was the most potent (i.v. ED50 11 μg/kg) in this series. E-1020 is presently under development for the treatment of congestive heart failure.

  合成了一系列1,2-二氢-5-咪唑[1,2-α]吡啶基-2(1H)-吡啶酮，并评估了它们的正性变力活性。1,2-二氢-5-咪唑[1,2-α]吡啶-6-基-6-甲基-2-氧-3-吡啶腈(11a)盐酸盐一水合物(E-1020)被发现是一种强效且选择性的磷酸二酯酶III抑制剂，以及一种长效、强效、口服活性正性变力剂。还制备了额外的咪唑[1,2-α]吡啶-2-基(3a)、-3-基(16)、-7-基(20)和-8-基(24a)化合物。将吡啶取代从2位改变到6位，静脉注射强心效力(ED50)从52增加到23 μg/kg，增加了2倍，而在3-、7-或8位取代则降低了效力。在2位异构体中，引入卤素基团增强了活性，3-氯-1,2-二氢-5-(6-氟咪唑[1,2-α]吡啶-2-基)-6-甲基-2(1H)吡啶酮(3u)是该系列中最强效的(静脉ED50 11 μg/kg)。E-1020目前正在开发用于治疗充血性心力衰竭。
• 5-(4-Thiazolyl)-6-alkyl-2(1H)-pyridinones and their cardiotonic use
  申请人：Sterling Drug Inc.

  公开号：US04469699A1

  公开（公告）日：1984-09-04

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-thiazolyl)-6-R.sub.1 -2(1H)-pyridinones (I), where R.sub.1 is alkyl having from one to four carbon atoms, R.sub.2 is hydrogen or methyl, R.sub.3 is hydrogen or alkyl having from one to three carbon atoms, Q is amino, carbamyl, carboxy, cyano or hydrogen, and Q' is alkyl having from one to four carbon atoms, amino or R.sub.4 NH where R.sub.4 is alkyl having from one to four carbon atoms, or acid-addition salts thereof where at least one of Q and Q' is amino or Q' is R.sub.4 NH, are useful as cardiotonics (I where Q is amino, cyano or hydrogen) and/or as intermediates (I where Q is cyano, carbamyl or carboxy). Also shown as intermediates are 1,2-dihydro-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-oxo-3-pyridinecarbonitriles (II), and, also, processes for preparing I and II.

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-thiazolyl)-6-R.sub.1 -2(1H)-pyridinones (I)，其中R.sub.1是具有一到四个碳原子的烷基，R.sub.2是氢或甲基，R.sub.3是氢或具有一到三个碳原子的烷基，Q是氨基、氨基甲酰基、羧基、氰基或氢，Q'是具有一到四个碳原子的烷基、氨基或R.sub.4 NH，其中R.sub.4是具有一到四个碳原子的烷基，或其酸盐加合物，其中Q和Q'中至少有一个是氨基或Q'是R.sub.4 NH，可用作心力补充剂（其中Q是氨基、氰基或氢）和/或作为中间体（其中Q是氰基、氨基甲酰基或羧基）。 还显示了1,2-二氢-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-氧代-3-吡啶腈（II）作为中间体，以及制备I和II的方法。
• Discovery and optimization of thienopyridine derivatives as novel urea transporter inhibitors
  作者：Yan Zhao、Min Li、Bowen Li、Shun Zhang、Aoze Su、Yongning Xing、Zemei Ge、Runtao Li、Baoxue Yang

  DOI：10.1016/j.ejmech.2019.03.060

  日期：2019.6

  further development. To overcome these shortcomings, the structure modification of thienoquinoline was carried out in this study, which led to the discovery of novel thienopyridine derivatives as specific urea transporter inhibitors. Further optimization obtained the promising preclinical candidate 8n with not only excellent inhibition effect on urea transporters and diuretic activity on rat model, but

  尿素转运蛋白（UTs）在尿液浓缩机制中起着重要作用，被公认为是开发具有保盐利尿活性的小分子抑制剂的新型靶标。硫喹啉衍生物是我们小组确定的一类新型UT-B抑制剂，在动物模型中起着重要的利尿作用。然而，差的溶解度和低的生物利用度限制了它的进一步发展。为了克服这些缺点，本研究对噻吩并喹啉进行了结构修饰，从而发现了新型噻吩并吡啶衍生物作为特定的尿素转运蛋白抑制剂。进一步的优化获得了有希望的临床前候选药物8n 对大鼠模型的尿素转运蛋白和利尿活性均具有优异的抑制作用，还具有一定的水溶性和Log P值。
• Hydroxylated inhibitors of HIV reverse transcriptase
  申请人：MERCK & CO. INC.

  公开号：EP0481802A1

  公开（公告）日：1992-04-22

  Novel biotransformed or synthetic hydroxy pyridinones inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts (where appropriate), pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

  新型生物转化或合成的羟基吡啶酮抑制HIV逆转录酶，在预防或治疗HIV感染以及治疗艾滋病方面具有用途，可以作为化合物、药学上可接受的盐（如适用）、药用组合成分，无论是否与其他抗病毒药物、抗感染药物、免疫调节剂、抗生素或疫苗结合。还描述了治疗艾滋病的方法以及预防或治疗HIV感染的方法。
• STUDIES WITH POLYFUNCTIONALLY SUBSTITUTED HETEROAROMATICS, A NEW ROUTE TO SYNTHESIS OF THIOPYRANO[3,2-C]PYRIDINE, THIOPYRANO[4,3-B]PYRIDINE, AND BIPYRIDYL DERIVATIVES
  作者：Fathi A. Abu-shanab、Mohamed R. Selim、Basil J. Wakefield、Mohamed H. Elnagdi

  DOI：10.1080/10426509708033707

  日期：1997.11

  Abstract Pyridine derivatives (4a, d, e) were reacted with carbon disulfide in dry tetrahydrofurane (THF) in the presence of potassium tert-butoxide under Argon to yield thiopyanopyridine derivatives (7, 10). Also (2a, 4c) were reacted with carbon disulfide under the same condition producing the dithioacetal derivatives (13) which were converted to hipyridyl derivatives (14) via reaction with cyanothioacetamide

  摘要 吡啶衍生物 (4a, d, e) 在无水四氢呋喃 (THF) 中，在叔丁醇钾存在下，在氩气下与二硫化碳反应，生成噻吩并吡啶衍生物 (7, 10)。同样(2a，4c)在相同条件下与二硫化碳反应，产生二硫代缩醛衍生物(13)，通过在异丙醇和异丙醇钠中与氰硫代乙酰胺反应将其转化为吡啶基衍生物(14)。